Abbott suspends study comparing HeartMate PHP against Abiomed's Impella

Mar. 16, 2021 11:39 AM ETAbbott Laboratories (ABT), ABMDABT, ABMDBy: Dulan Lokuwithana, SA News Editor3 Comments
  • According to an update posted on the federal register for clinical trials, Abbott (ABT +0.2%) has suspended the recruitment for SHIELD II clinical trial citing reports of ‘decreased impeller speed at the end of a procedure.’
  • The randomized trial targeting to enroll 716 participants compared Abbott’s HeartMate PHP catheter with any of Impella pumps of Abiomed (ABMD +1.0%) for use in high-risk percutaneous coronary intervention (“PCI”).
  • In late 2019, Abiomed rose when the trial’s expected completion date was pushed back to December 2021.

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.